Payment overview · 2025
General Payments
$263.70
13 reported records · 11 companies
Healthcare provider profile · identity verified
Timothy Ray Olive, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · POTEAU, OK · NPI 1033418439
Verified facts
What the public records show
CMS Open Payments records show Timothy Ray Olive, ARNP received $263.70 in general payments during 2025 across 13 reported records.
Lilly USA, LLC accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.25 | 12.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.08 | 12.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.25 | 11.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.30 | 10.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.98 | 9.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.34 | 8.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.23 | 7.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.55 | 7.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.56 | 6.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.09 | 6.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.07 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $263.70 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $59.06 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.30 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 180 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
180 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 384 | 122 |
| Omeprazole | Omeprazole | 375 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 327 | 95 |
| Gabapentin | Gabapentin | 297 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 281 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 275 | 91 |
| Lisinopril | Lisinopril | 250 | 74 |
| Montelukast Sodium | Montelukast Sodium | 242 | 68 |
| Potassium Chloride | Potassium Chloride | 226 | 65 |
| Tramadol Hcl | Tramadol Hcl | 216 | 74 |
| Metformin Hcl | Metformin Hcl | 214 | 64 |
| Furosemide | Furosemide | 203 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 56 |
| Meloxicam | Meloxicam | 183 | 70 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 180 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 51 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 154 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 53 |
| Trazodone Hcl | Trazodone Hcl | 148 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 41 |
| Prednisone | Prednisone | 130 | 94 |
| Sertraline Hcl | Sertraline Hcl | 129 | 44 |
| Eliquis | Apixaban | 114 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 36 |
| Allopurinol | Allopurinol | 107 | 30 |
| Carvedilol | Carvedilol | 106 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 33 |
| Mounjaro | Tirzepatide | 96 | 17 |
| Losartan Potassium | Losartan Potassium | 95 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 25 |
| Ozempic | Semaglutide | 86 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 26 |
| Metformin Hcl Er | Metformin Hcl | 75 | 25 |
| Pregabalin | Pregabalin | 70 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 18 |
| Azithromycin | Azithromycin | 65 | 55 |
| Celecoxib | Celecoxib | 63 | 21 |
| Methylprednisolone | Methylprednisolone | 63 | 60 |
| Glipizide | Glipizide | 62 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 60 | 16 |
| Simvastatin | Simvastatin | 60 | 16 |
| Spironolactone | Spironolactone | 53 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 17 |
| Finasteride | Finasteride | 50 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 29 |
| Ibuprofen | Ibuprofen | 47 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 47 | 13 |
| Xarelto | Rivaroxaban | 47 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 12 |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 43 | 16 |
| Tradjenta | Linagliptin | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 36 |
| Nitroglycerin | Nitroglycerin | 40 | 30 |
| Buspirone Hcl | Buspirone Hcl | 39 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Nystatin | Nystatin | 32 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 13 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | 13 |
| Baclofen | Baclofen | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | 12 |
| Atenolol | Atenolol | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 24 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 18 |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | 12 |
| Acyclovir | Acyclovir | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Cilostazol | Cilostazol | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Torsemide | Torsemide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $263.70 · 13 records | Lilly USA, LLC | AIRSUPRA, AREXVY, Dexcom G6 Transmitter, FANAPT, GEMTESA, Kerendia, MOUNJARO, REXULTI, TRELEGY ELLIPTA, Wegovy, YUPELRI, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error